Abstract
In May 2005, the Food and Drug Administration (FDA) issued draft guidance on the type of information to be posted on its new “Drug Watch” website—a site intended to identify drugs for which it is actively evaluating early safety signals. At this time, the FDA plans only to post information on drug products regulated by the Center for Drug Evaluation and Research, therefore vaccines, blood products and medical devices shall be excluded.
Disciplines
Antitrust and Trade Regulation
Date of this Version
June 2005
Recommended Citation
Mark Heller, Hollie Baker, Robert Barry, James Burling, and Suyong Kim, "PHARMABULLETIN Issue 2, Summer 2005" (June 2005). Wilmer Cutler Pickering Hale and Dorr Antitrust Series. Working Paper 11.
https://law.bepress.com/wilmer/art11